Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2019

View Archived Issues

Anti-influenza drug candidate targeting the hemagglutinin stalk of influenza viruses

Flavonoid baicalin upregulates miR-126-5p: a potential therapeutic strategy against atherosclerosis

Hypertensive rats are more sensitive to TRPM8-mediated relaxation of the pudendal artery

Heterozygous COL4A1 mutations are a potential autosomal dominant cause of CAKUT

Circular RNA hsa_circ_0006848 identified as a potential diagnostic biomarker of early gastric cancer

Phage-based nanoligands wrap up drugs for delivery across BBB

Pliant enters collaboration and license agreement with Novartis for PLN-1474 in NASH

Interim results from phase I trial of chimeric HA-based universal influenza virus vaccine candidates

First patient dosed in phase IIb ReNeu study of mirdametinib in children and adults with NF1-PN

FDA approves Botox for pediatric patients with lower limb spasticity

Scynexis announces amendment to protocol for ongoing FURI study of ibrexafungerp

EphB4 as a novel biomarker of imatinib resistance in CML

Researchers identify 7B2CT as potential biomarker in chronic OA pain

Serum chemerin shows potential as marker to diagnose and grade NAFLD

SUVN-1702012 for psychiatric disorders balancing antipsychotic and motor side effects

New glutamate receptor modulator DT-095435 shows impressive in vivo antiparkinsonian potential

Aurigene Discovery Technologies divulges CDK12 and CDK13 inhibitors

Janssen Pharmaceutica presents new ionotropic glutamate GluN2B receptor antagonists

AbbVie and Galapagos identify mutant CFTR correctors for cystic fibrosis

Merck KGaA synthesizes new IRAK inhibitors

Japan Tobacco describes new SLC5A1 inhibitors

Syros reports new data from phase II trial of SY-1425 in newly diagnosed unfit AML

New phase I trial investigates MB-108 in recurrent glioblastoma multiforme

NIAID awards contract to UAB to study Bexsero for gonorrhea prevention

FDA approves Baxdela for community-acquired bacterial pneumonia

European Commission approves Xospata for relapsed or refractory FLT3 mutation-positive AML

FDA clears IND for phase I trial of SQZ-PBMC-HPV